Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dr Reddys Laboratories ADR repsg 1 Ord Shs RDY

Healthcare
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The... see more

Recent & Breaking News (NYSE:RDY)

Dr. Reddy's to Acquire Select Anti-Allergy Brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan  

Business Wire November 28, 2020

Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

Business Wire November 12, 2020

Dr. Reddy's Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor

Business Wire November 9, 2020

Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

Business Wire October 29, 2020

Dr. Reddy's Laboratories Announces Appointment of New Chief Financial Officer

Business Wire October 28, 2020

Dr. Reddy's Q2 & H1 FY21 Financial Results

Business Wire October 28, 2020

Dr. Reddy's announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

Business Wire October 20, 2020

Dr. Reddy's and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

Business Wire October 17, 2020

Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

Business Wire October 12, 2020

Dr. Reddy's Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission Targets

Business Wire October 5, 2020

Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

Business Wire October 3, 2020

Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market

Business Wire October 1, 2020

Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

Business Wire September 26, 2020

Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

Business Wire September 25, 2020

Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

Business Wire September 17, 2020

Dr. Reddy's announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

Business Wire September 17, 2020

RDIF and Dr. Reddy's to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

Business Wire September 16, 2020

Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market

Business Wire September 9, 2020

Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

Business Wire September 7, 2020

Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

Business Wire September 3, 2020